Lesson 1: What the IRA will do to biotech

Lesson 2: The good, the bad, and the ugly

Lesson 3: The IRA's effect on valuations, and why GCEAs are a company's best defense

Lesson 4: Getting 9 to 13

Lesson 5: Why drug companies can't just charge more

Lesson 6: "I thought this was only about medicare"... NOPE